Public petition from the people of north Staffordshire on the availability of prescription drugs for the treatment of Alzheimer's disease. (Circulated with the Vote for 6 December)

Public petition from the people of north Staffordshire on the availability of prescription drugs for the treatment of Alzheimer's disease. (Circulated with the Vote for 6 December)

To ask the Secretary of State for Health (1) what representations she has received on the availability of disease modifying therapies for people with multiple sclerosis in Staffordshire; and if she will make a statement;

To ask the Secretary of State for Health (1) what representations she has received on the availability of disease modifying therapies for people with multiple sclerosis in Staffordshire; and if she will make a statement;

(2) if she will meet the MS Society to discuss the terms of reference of the North Staffordshire Review Panel assessing the cost-effectiveness of disease modifying therapies for people with multiple sclerosis.

(2) if she will meet the MS Society to discuss the terms of reference of the North Staffordshire Review Panel assessing the cost-effectiveness of disease modifying therapies for people with multiple sclerosis.

To ask the Secretary of State for Health (1) whether the National Institute for Health and Clinical Excellence assesses qualitative research in its appraisal of technologies and treatments;

To ask the Secretary of State for Health (1) whether the National Institute for Health and Clinical Excellence assesses qualitative research in its appraisal of technologies and treatments;

(3) how many people with Alzheimer's disease have been treated with anti-cholinesterase drugs since they were licensed in the UK.

(3) how many people with Alzheimer's disease have been treated with anti-cholinesterase drugs since they were licensed in the UK.

(2) whether the membership of the National Institute for Health and Clinical Excellence appraisal committee responsible for the appraisal of drug treatments for Alzheimer's disease includes dementia specialists.

(2) whether the membership of the National Institute for Health and Clinical Excellence appraisal committee responsible for the appraisal of drug treatments for Alzheimer's disease includes dementia specialists.

To ask the Secretary of State for Health what assessment she has made of the likely impact of the National Institute for Health and Clinical Excellence's recommendations on use of drug treatments for Alzheimer's disease on those in the early stages of the disease.

To ask the Secretary of State for Health what assessment she has made of the likely impact of the National Institute for Health and Clinical Excellence's recommendations on use of drug treatments for Alzheimer's disease on those in the early stages of the disease.

(2) what the cost to the NHS of prescribing drug treatments for people in the moderate stages of Alzheimer's disease was in 2004–05;

(2) what the cost to the NHS of prescribing drug treatments for people in the moderate stages of Alzheimer's disease was in 2004–05;

To ask the Secretary of State for Health (1) how many people were prescribed Ebixa on the NHS in the last three years for which figures are available; and what the cost to the NHS for Ebixa was in each year;

To ask the Secretary of State for Health (1) how many people were prescribed Ebixa on the NHS in the last three years for which figures are available; and what the cost to the NHS for Ebixa was in each year;

To ask the Secretary of State for Health (1) what research has been evaluated on the impact of drug treatments for Alzheimer's disease on entry into full-time care;

To ask the Secretary of State for Health (1) what research has been evaluated on the impact of drug treatments for Alzheimer's disease on entry into full-time care;

(2) what assessment has been made of the potential impact of the restriction of drug treatments for Alzheimer's disease proposed by the National Institute for Health and Clinical Excellence on the requirement for (a) care services, (b) care homes and (c) carer time.

(2) what assessment has been made of the potential impact of the restriction of drug treatments for Alzheimer's disease proposed by the National Institute for Health and Clinical Excellence on the requirement for (a) care services, (b) care homes and (c) carer time.

To ask the Secretary of State for Health, what guidance was available in the (a) 1970s and (b) 1980s in respect of routine recording of myodil injections on medical records; and if he will make a statement.

To ask the Secretary of State for Health, what guidance was available in the (a) 1970s and (b) 1980s in respect of routine recording of myodil injections on medical records; and if he will make a statement.

To ask the Secretary of State for Health, what steps he is taking to reduce waiting times for cardiology appointments; and if he will make a statement.

To ask the Secretary of State for Health, what steps he is taking to reduce waiting times for cardiology appointments; and if he will make a statement.

To ask the Secretary of State for Health, what his policy is on routine follow-up tests for people who have suffered heart attacks and suspected heart attacks; and if he will make a statement.

To ask the Secretary of State for Health, what his policy is on routine follow-up tests for people who have suffered heart attacks and suspected heart attacks; and if he will make a statement.

To ask the Secretary of State for Health, what the average waiting times have been in each of the last six years for cardiology appointments; and if he will make a statement. - Inc table.

To ask the Secretary of State for Health, what the average waiting times have been in each of the last six years for cardiology appointments; and if he will make a statement. - Inc table.

To ask the Secretary of State for Health, what steps the Government is taking to improve facilities for people suffering from chronic fatigue syndrome; and if he will make a statement. - Inc figures.

To ask the Secretary of State for Health, what steps the Government is taking to improve facilities for people suffering from chronic fatigue syndrome; and if he will make a statement. - Inc figures.

To ask the Secretary of State for Defence, how many injured servicemen have been returned from the Gulf to the United Kingdom; and if he will make a statement on (a) medical and (b) convalescence treatment available to them.

To ask the Secretary of State for Defence, how many injured servicemen have been returned from the Gulf to the United Kingdom; and if he will make a statement on (a) medical and (b) convalescence treatment available to them.

To ask the Secretary of State for Defence, if he will make a statement on his medical contingency plans in respect of Iraq with particular reference to military hospitals, after care and convalescence contingency planning for armed forces personnel (a) not involved in Iraq, and (b) based in Iraq.

To ask the Secretary of State for Defence, if he will make a statement on his medical contingency plans in respect of Iraq with particular reference to military hospitals, after care and convalescence contingency planning for armed forces personnel (a) not involved in Iraq, and (b) based in Iraq.

To ask the Secretary of State for Health, what steps he is taking to ensure health authorities implement NICE's recommendations on the prescription of anti-TNF for children and adults with severe rheumatoid arthritis.

To ask the Secretary of State for Health, what steps he is taking to ensure health authorities implement NICE's recommendations on the prescription of anti-TNF for children and adults with severe rheumatoid arthritis.

To ask the Secretary of State for Health, what further plans he has to help sufferers of arthritis.

To ask the Secretary of State for Health, what further plans he has to help sufferers of arthritis.